Comparative study of weekly and three‑weekly neoadjuvant carboplatin in triple‑negative breast cancer: retrospective analysis in real‑world settings

• Ana Isabel Martin Quesada ^[1] ; Natalia Rodríguez Pérez ^[1] ; Alicia Herrero Márquez ^[1] ; Isaac Núñez Hernández ^[1] ; Elisenda Llabres Valentí ^[2] ; Cristina María Montesdeoca Godoy ^[2] ; Carla Martín Abreu ^[3] ; Cristina Alemán Sánchez ^[3] ; Josefina Cruz Jurado ^[3] ; María Hernández Sosa ^[4] ; Melody Marrero García ^[4] ; Cristina Victoria Del Pino Hernández ^[5] ; Samuel José Hernández Sarmiento ^[5] ; Alejandra Rodríguez Capote ^[6] ; Lina Pérez Méndez ^[7]
  1. [1] Medical Oncologist, University Hospital Nuestra Señora de Candelaria, Ctra. Gral. del Rosario, 145, 38010 Santa Cruz de Tenerife, Spain
  2. [2] Medical Oncologist, Insular Materno-Infantil University Hospital, Avenida Marítima del Sur, S/N, 35016 Las Palmas de Gran Canaria, Las Palmas, Spain
  3. [3] Medical Oncologist, University Hospital of the Canary Islands, Carretera Ofra S/N, 38320 La Laguna, Santa Cruz de Tenerife, Spain
  4. [4] Medical Oncologist, Doctor Negrín University Hospital, C. Pl. Barranco de La Ballena, S/N, 35010 Las Palmas de Gran Canaria, Las Palmas, Spain
  5. [5] Medical Oncologist, Virgen de La Peña General Hospital, Carretera del Aeropuerto, Km 1, 35600 Puerto del Rosario, Las Palmas, Spain
  6. [6] Medical Oncologist, University Hospital de La Palma, LP-3, 28, 38713 Breña Alta, Santa Cruz de Tenerife, Spain
  7. [7] Department of Clinical Epidemiology and Biostatistics, Research Unit, University Hospital Nuestra Señora de Candelaria Tenerife and Primary Care Management, Santa Cruz de Tenerife, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 8, 2024, págs. 2070-2074
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Purpose Tri-weekly carboplatin is an established neoadjuvant treatment for triple-negative breast cancer, enhancing pathological complete response (pCR) and overall survival. This study explores if weekly carboplatin provides lower toxicity and comparable pCR rates.

    Methods/patients A retrospective multicenter study (January 2021 to March 2023) compares outcomes of weekly and triweekly carboplatin.

    Results Among 104 participants, 60% received weekly and 40% tri-weekly treatments. Weekly administration had fewer discontinuations (56.5 vs. 70.7%, p = 0.154). Both schedules exhibited similar overall toxicity (p = 0.087), with slightly higher grade 3–4 toxicity in the tri-weekly group (56.1 vs. 48.4%, p = 0.126). Hematological toxicity was comparable, but the weekly group experienced more diarrhea (p = 0.432) and asthenia (p = 0.012). Weekly treatment correlated with more frequent breast-conserving surgeries (p = 0.004). pCR rates were 50% with weekly and 61% with tri-weekly regimens (p = 0.186).

    Conclusions Weekly carboplatin exhibited comparable toxicity, a trend toward fewer interruptions, and similar pCR rates. Prospective studies are essential for validating these findings.